The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

This investigator-initiated study will include a total of 55 patients with early-stage prostate cancer. The patients are treated with MRI-guided Focal Laser Ablation (MRgFLA) at the Toronto General Hospital, Canada. During the presentation at RSNA Dr Ghai shared 24-month data from the study including 25 patients. 

The abstract is published on the RSNA website with the title:

S5-SSGU01-1 – MRI Guided Focal Laser Ablation (MRgFLA) For Localized Intermediate-Risk Prostate Cancer: Results of A Phase II Trial.

The authors conclude that targeted focal therapy of intermediate-risk prostate cancer performed under MRgFLA is safe with encouraging 2 year oncological and functional outcomes.